Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;34(5):1289-1300.
doi: 10.1007/s13577-021-00560-w. Epub 2021 May 31.

Novel cell-based therapies in inflammatory bowel diseases: the established concept, promising results

Nikoo Hossein-Khannazer  1 , Shukoofeh Torabi  2 , Ramin Hosseinzadeh  3 , Shabnam Shahrokh  4 , Hamid Asadzadeh Aghdaei  4 , Arash Memarnejadian  5 , Nadir Kadri  6 , Massoud Vosough  7
Affiliations
Review

Novel cell-based therapies in inflammatory bowel diseases: the established concept, promising results

Nikoo Hossein-Khannazer et al. Hum Cell. 2021 Sep.

Abstract

Inflammatory bowel diseases (IBDs) are chronic and relapsing disorders that affect the quality of life in many individuals around the world. Over the past few years, the prevalence of IBDs is substantially rising which might pose a considerable social and economic burden on health systems. Progresses in the management of chronic inflammatory diseases lead to prolonged remission phase and decreased hospitalization rate. However, during treatment, many patients become refractory to conventional therapies. Recently, advanced approaches using somatic cell therapy medicinal products (SCTMPs) including immune and stem cell-based therapies have drawn many researchers' attentions. Promising results from recent trials, alongside with the emerging market indicated that these therapeutic approaches could be an alternative and promising treatment to conventional therapies. In this review, we will discuss recent advances in cell-based therapies, which have been developed for treatment of IBDs. In addition, the global emerging market and the novel products in this field are highlighted.

Keywords: Cell therapy; Cell-based products; Immune therapy; Inflammatory bowel diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing interests that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
New therapeutic avenues in inflammatory Bowel Diseases (IBDs). A immunosuppressive therapies, such as 6-mercaptopurine (6-MP), azathioprine (AZA), and methotrexate (MTX), induce anti-inflammatory effects through suppression of T cell function and natural killer cell activity. B Monoclonal Antibody (mAb) -Based Biological Therapies against prototypical pro-inflammatory cytokines, chemokines and receptors, such as TNF-α, IL-12-R and CD19. C Allogeneic or autologous Hematopoietic Stem Cells can migrate to damaged tissues and differentiate to epithelial or immune-modulatory cells to restore normal mucosa and tissue integrity. D specialized immune cells, such as Regulatory T cell (Treg) and Tolerogenic Dendritic cells (Tol-DCs), help to repair intestinal mucosal tissues by damping inflammation and effector T cells activity. E Mesenchyme stromal cells (MSCs) can control IBD through facilitating tissue regeneration, supporting angiogenesis and limiting inflammation
Fig. 2
Fig. 2
Approved Mesenchyme Stromal Cells (MSCs) based products for treatment Refectory Crohn´s disease (CD)
See this image and copyright information in PMC

References

    1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–317. doi: 10.1038/nature10209. - DOI - PMC - PubMed
    1. Cho JH, Abraham C. Inflammatory bowel disease genetics: Nod2. Annu Rev Med. 2007;58:401–416. doi: 10.1146/annurev.med.58.061705.145024. - DOI - PubMed
    1. Wawrzyniak M, Scharl M. Genetics and epigenetics of inflammatory bowel disease. Swiss Med Wkly. 2018;148:14671. - PubMed
    1. Loddo I, Romano C. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Front Immunol. 2015;6:551. doi: 10.3389/fimmu.2015.00551. - DOI - PMC - PubMed
    1. De Mattos B, et al. Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediators Inflamm. 2015;493012(1155):2015. - PMC - PubMed